Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

10/15/2020 | 09:16am EDT

Item 8.01 Other Events.

On October 15, 2020, Sage Therapeutics, Inc. (the "Company") issued a press release announcing interim, topline data from the Company's ongoing Phase 3 open-label SHORELINE study evaluating zuranolone (SAGE-217) in the treatment of patients with major depressive disorder. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit
  No.       Description

99.1          Press release issued by Sage Therapeutics, Inc. on October 15, 2020.


104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about SAGE THERAPEUTICS, INC.
06/10SAGE THERAPEUTICS, INC.  : Submission of Matters to a Vote of Security Holders (..
AQ
05/20SAGE THERAPEUTICS  : Joins MTV Entertainment Group and More Than 1,300 Leading O..
BU
05/13SAGE THERAPEUTICS TO HOST SAGE SCIEN : SAGE-718 In Depth
BU
05/05SAGE THERAPEUTICS  : Oppenheimer Adjusts Sage Therapeutics PT to $100 From $102,..
MT
05/05SAGE THERAPEUTICS  : RBC Capital Adjusts Sage Therapeutics' Price Target to $84 ..
MT
05/05SAGE THERAPEUTICS  : Wedbush Adjusts Price Target on Sage Therapeutics to $90 Fr..
MT
05/04SAGE THERAPEUTICS  : Company on-track to initiate placebo-controlled Phase 2 tri..
PU
05/04SAGE THERAPEUTICS  : Q1 Net Loss Narrows
MT
05/04SAGE THERAPEUTICS  : Management's Discussion and Analysis of Financial Condition..
AQ
05/04SAGE THERAPEUTICS, INC.  : Results of Operations and Financial Condition, Financ..
AQ
More news